The functionality of cytotoxic T lymphocytes (CTLs) may be reactivated, and their ability to combat tumor cells may be strengthened through the administration of monoclonal antibodies (mAbs) that impede the PD-1/PD-L1 pathway [57]. The gene discussed is CD274; the disease is neoplasm.